Erasca (ERAS) Surges 8.9% on Promising Cancer Trial Results
724FinanceEge Kaan
Key Highlights
Erasca (ERAS), kanser tedavisi için umut verici klinik deney sonuçlarıyla piyasa tepkisini tetikledi. Hisse, 8.94% artışla $19.50 seviyesine kapandı.
Erasca (ERAS) stock surged 8.94% to close at $19.50, driven by promising clinical trial results for its cancer treatment candidate. ERAS-0015 showed a 57% tumor reduction in seven pancreatic cancer patients after eight weeks.
The results position Erasca as a key player in cancer therapy. Additional data on ERAS-0015's combination with panitumumab is expected in H1 2027. Investors are valuing the drug's efficacy and safety profile against competitors like daraxonrasib.
Related News & Analysis
View All →
Binance Employees Arrested in UAE: Regulatory Pressure Intensifies
Moderna's Cancer Vaccine Euphoria Hits Profit-Taking Wall: $18 Billion Wipeout
Singh Joins Mayfield: A New Era for Chip Investments
Ramp Unveils Model Router, Steering the AI Landscape into a New Era
WNBA’s Landmark Pay Raise: 364% Surge in Player Wages Sparks Labor Milestone
Gen Z Rewrites the American Dream in the Great Postponement
Latest Market News
All News →
Castelion Secures $13 Billion Valuation to Accelerate Hypersonic Missile Production
KAMUYU AYDINLATMA PLATFORMU Sermaye Piyasası Kurulu Tedbir Kararı / BAYRK - Sermaye Piyasası Kurulu Tedbir Kararı
Binance Employees Arrested in UAE: Regulatory Pressure Intensifies
İran, ABD Yaptırımlarını 'Ekonomik Terörizm' Dedi: Küresel Finansal Tabloları Huzursuzlaştırıyor
[YYAPI] YEŞİL YAPI ENDÜSTRİSİ A.Ş. Katılım Finansı İlkeleri Bilgi Formu - Katılım Finansı İlkeleri Bilgi Formu